Oppenheimer analyst Timothy Horan downgrades 8×8 (NYSE:EGHT) from Outperform to Perform.
JMP Securities Reiterates Market Outperform on Ocular Therapeutix, Maintains $12 Price Target
JMP Securities analyst Jonathan Wolleben reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and maintains $12 price target.